Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 11/20 | 0.34 |
| ▸ | CSNK1D | P48730 | 3/20 | 0.33 |
| ▸ | CSNK1E | P49674 | 3/20 | 0.33 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.33 |
| ▸ | RPA1 | P27694 | 1/20 | 0.32 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.32 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.32 |
| ▸ | AR | P10275 | 1/20 | 0.32 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.32 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.32 |
| ▸ | BRAF | P15056 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL419511 | 0.90 | RPA1 (0.35) | PGRRPA1BRAF | |
| SCHEMBL417758 | 0.90 | PGR (0.40) | PGRCSNK1DCSNK1ENR3C1 | |
| SCHEMBL415935 | 0.87 | METAP2 (0.35) | PGRCSNK1E | |
| SCHEMBL421837 | 0.86 | PGR (0.32) | PGRFFAR2 | |
| SCHEMBL418233 | 0.83 | HSP90AA1 (0.40) | RPA1BRAF | |
| SCHEMBL420239 | 0.83 | PDE4B (0.37) | PGRRPA1BRAF | |
| SCHEMBL421343 | 0.82 | PGR (0.39) | PGR | |
| SCHEMBL417480 | 0.81 | PDE4B (0.38) | — | |
| SCHEMBL422505 | 0.80 | MAPK14 (0.41) | PGRCSNK1DCSNK1EFFAR2 | |
| SCHEMBL418259 | 0.80 | PDE4B (0.37) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2376479-B1 | SUBSTITUTED FURANCARBOXAMIDES, AND USE THEREOF | AICURIS GMBH & CO KG (DE) | 2016-03-02 | — | — | EP | disclosed |
| EP-2376479-B1 | SUBSTITUTED FURANCARBOXAMIDES, AND USE THEREOF | AICURIS GMBH & CO KG (DE) | 2016-03-02 | — | — | EP | disclosed |
| US-8324268-B2 | Substituted furancarboxamides, and use thereof | AICURIS GMBH & CO. KG (DE) | 2012-12-04 | — | — | US | disclosed |
| US-8324268-B2 | Substituted furancarboxamides, and use thereof | AICURIS GMBH & CO. KG (DE) | 2012-12-04 | — | — | US | disclosed |
| US-8324268-B2 | Substituted furancarboxamides, and use thereof | AICURIS GMBH & CO. KG (DE) | 2012-12-04 | — | — | US | disclosed |
| US-20120022059-A1 | SUBSTITUTED FURANCARBOXAMIDES, AND USE THEREOF | AICURIS GMBH & CO. KG (DE) | 2012-01-26 | — | — | US | disclosed |
| US-20120022059-A1 | SUBSTITUTED FURANCARBOXAMIDES, AND USE THEREOF | AICURIS GMBH & CO. KG (DE) | 2012-01-26 | — | — | US | disclosed |
| US-20120022059-A1 | SUBSTITUTED FURANCARBOXAMIDES, AND USE THEREOF | AICURIS GMBH & CO. KG (DE) | 2012-01-26 | — | — | US | disclosed |
| EP-2376479-A1 | SUBSTITUTED FURANCARBOXAMIDES, AND USE THEREOF | AiCuris GmbH & Co. KG (DE) | 2011-10-19 | — | — | EP | disclosed |
| WO-2010075957-A1 | SUBSTITUTED FURANCARBOXAMIDES, AND USE THEREOF | AICURIS GMBH & CO. KG (DE) | 2010-07-08 | — | — | WO | disclosed |
| WO-2010075957-A1 | SUBSTITUTED FURANCARBOXAMIDES, AND USE THEREOF | AICURIS GMBH & CO. KG (DE) | 2010-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022059-A1 | SUBSTITUTED FURANCARBOXAMIDES, AND USE THEREOF | AADAC, DDC, TPMT | PGR 3356/4885CSNK1D 3696/4885CSNK1E 2989/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.